Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: The disclosure to methods for treating seizure or an epilepsy disorder comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.

Abstract: A method of synthesizing copolymers is provided. The method can include coupling a degradable polymer to a poly(amino acid) and then deprotecting the copolymer if the poly(amino acid) contains protected side chains. Copolymer compositions are provided. These compositions include PLGA-PLL copolymers, PLGA-PLL-cbz copolymers, and copolymers of a polyester with a carboxylic acid end group coupled to a poly(amino acid) with an amine group. The compositions may include therapeutic blends and formulations of copolymers.

Abstract: Methods of controlled delivery of bioactive therapeutics are provided. Compositions comprising therapeutic implants are provided.

Abstract: Disclosed herein are biodegradable hydrogel network containing covalently crosslinked bonds between oligomeric poly(thiol) compounds and oligomeric poly(Michael acceptors). The hydrogels do not substantially change shape upon exposure to aqueous solutions, and as such as suitable for local drug delivery to sensitive tissue areas.

Abstract: Injectable mediums and methods for preparing and administering an injectable medium comprising therapeutic cells, and optionally one or more therapeutic or diagnostic substance, suitable for injection into an anatomical space of a human or animal subject, comprising hyaluronic acid in concentrations of 0.5 weight percent to 1.0 weight percent having a molecular weight of about ?700 kDa to about 1,900 kDa and a storage modulus within the range of 5-25 Pa, which injectable mediums and methods prevent cell settling during transportation and storage of such injectable mediums comprising therapeutic cells, and optionally therapeutic or diagnostic substances; promote cell survival; facilitate administration of homogeneous injectable mediums comprising therapeutic cells, in particular NSCs; and enable rapid clearance by the body following injection, so as not to interfere with cellular integration with surrounding tissue.

Abstract: Injection devices and methods for delivering a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium into an anatomical space of an animal or human subject, particularly a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium into the spinal cord of a subject and to deliver a trail of therapeutic cells and/or one or more therapeutic substances or diagnostic substances or injectable medium inside the spinal cord, to treat an injury or disorder of the central nervous system requiring injection of cells and/or one more therapeutic substances. The devices and methods are useful for the treatment of a variety of traumas, conditions and diseases, in particular, spinal cord injuries, amyotrophic lateral sclerosis, multiple sclerosis and spinal ischemia as well as other spinal cord degenerative conditions and pathologies.

Abstract: A method of synthesizing copolymers is provided. The method can include coupling a degradable polymer to a poly(amino acid) and then deprotecting the copolymer if the poly(amino acid) contains protected side chains. Copolymer compositions are provided. These compositions include PLGA-PLL copolymers, PLGA-PLL-cbz copolymers, and copolymers of a polyester with a carboxylic acid end group coupled to a poly(amino acid) with an amine group. The compositions may include therapeutic blends and formulations of copolymers.

Abstract: Methods of controlled delivery of bioactive therapeutics are provided. Compositions comprising therapeutic implants are provided.